TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7506181
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol
Study: 16415311
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg
Study: 16939998
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment in non-obese participants
Study: 22136660
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) administered to mothers during late pregnancy
Study: 2044394
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (40 mg, 3 times daily)
Study: 12011124
Drug: ACVBP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACVBP chemotherapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Study: 4047707
Drug: Ibuprofen, 400
Normalized name: Ibuprofen, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 400 mg
Study: 8459971
Drug: Sodium etidronate
Normalized name: Sodium etidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium etidronate 400 mg/day for 14 days followed by calcium carbonate 500 mg/day for 42 days plus norethindrone 2.5 mg/day
Study: 19835582
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of GILP
Study: 19835582
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of GILP
Study: 16462287
Drug: 3-dose schedule
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose schedule initiated in the neonatal period
Study: 211983
Drug: Fluphenazine enanthate
Normalized name: Fluphenazine Enanthate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine enanthate high-dose (1 ml) with family therapy
Study: 8241697
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (2 mg/kg per day)
Study: 17357181
Drug: 12-week controlled
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week controlled antidepressant monotherapy trial
Study: 15735613
Drug: Immediate-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release metoprolol
Study: 26755098
Drug: Simultaneous intake
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous intake of grass and ragweed SLIT tablets
Study: 23214314
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education management and lifestyle intervention (on the basis of group B's therapy)
Study: 16885042
Drug: Thalidomide 400
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 400 mg/d
Study: 12865592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HRT or other treatments)
Study: 12201921
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (1 mg kg(‐1), IM)
Study: 3908132
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg/day for 3 weeks
Study: 27403058
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution used for irrigation
Study: 12933390
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus clonidine 1 micro g/mL
Study: 10739849
Drug: Elevated maternal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated maternal total homocysteine concentrations (fasting >18.3 micromol/l and/or 6 h after methionine load >61.5 micromol/l)
Study: 27102981
Drug: All routes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All routes of administration
Study: 27305830
Drug: Medication continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication continuation (quetiapine 400 mg/day)
Study: 27305830
Drug: Medication discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication discontinuation (placebo)
Study: 2337035
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg twice daily
Study: 23904009
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment (N=15)
Study: 29274727
Drug: Guideline antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline antiplatelet therapy (clopidogrel alone or combined aspirin and dipyridamole)
Study: 26079743
Drug: Guideline antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline antiplatelet therapy
Study: 1290434
Drug: Danazol 50
Normalized name: danazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 50 mg and 100 mg maintenance doses
Study: 2921588
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 3.0 mg/70 kg
Study: 2921588
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 6.0 mg/70 kg
Study: 2921588
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (all doses)
Study: 3498395
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol injection at 15 seconds
Study: 3498395
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol injection at 45 seconds
Study: 1856249
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol (60 mg elemental iron as tablets)
Study: 15901232
Drug: Resilient Peer
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resilient Peer Treatment (RPT)
Study: 12928941
Drug: Anakinra (Kineret®)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra (Kineret®) as monotherapy or in combination with methotrexate
Study: 19478715
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of prednisolone
Study: 19478715
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of dexamethasone
Study: 21898340
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS) 800 mg once daily for 6 months
Study: 3189700
Drug: Intravenous crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous crystalline penicillin for 5 days
Study: 17005801
Drug: Daptomycin 10
Normalized name: daptomycin 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 10 mg/kg once daily for 14 days
Study: 17005801
Drug: Daptomycin 12
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 12 mg/kg once daily for 14 days
Study: 17005801
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 or 8 mg/kg once daily for 4 days
Study: 27480628
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest computed tomography (LDCT)
Study: 10877193
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) infusion
Study: 19767791
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg diazepam (HIGH)
Study: 17351746
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg Afimoxifene gel
Study: 25185574
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg alum‐adjuvanted OspA antigen
Study: 7870932
Drug: Cocaine administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administration
Study: 17118828
Drug: Topical cooling
Normalized name: Castiva Cooling Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cooling with ice‐slush
Study: 15302008
Drug: Tezosentan 25
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 25 mg/h
Study: 2178298
Drug: AVP antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AVP antagonist [d(CH2)5 Tyr(Me)AVP] 10 micrograms/kg
Study: 7846463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin administered at 1900 hours
Study: 7846463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin administered at 2100 hours
Study: 2113590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of long-term and short-term instillation protocols
Study: 19447387
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) treatment
Study: 2486583
Drug: Supplemental boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental boluses of 4 ml of 0.5% bupivacaine
Study: 24648506
Drug: Amoxicillin twice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin twice daily (50 mg/kg/day)
Study: 18803866
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Study: 11369828
Drug: Beta-blocker (atenolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (atenolol)
Study: 11369828
Drug: Non-dihydropyridine calcium
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-dihydropyridine calcium channel blocker (verapamil)
Study: 9416381
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate formulation without Veegum
Study: 22065400
Drug: bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosutinib 500 mg plus ketoconazole (supratherapeutic)
Study: 16020405
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/day (increased to 160 mg as tolerated)
Study: 8686411
Drug: High potency
Normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High potency pancreatin (9 g, 3 g x 3 times) for approximately 1 month
Study: 22941193
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO(3)) 0.3 g kg(‐1)
Study: 11518628
Drug: Topiramate low
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate low dosage (100 mg daily)
Study: 9443517
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral dose of D-amphetamine
Study: 9443517
Drug: Low oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oral dose of D-amphetamine
Study: 2196193
Drug: Glipizide 15
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide 15 mg daily
Study: 17609429
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Miglustat + Imiglucerase)
Study: 16373264
Drug: ACIST injection
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIST injection system (n=252)
Study: 2649122
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.5 mg
Study: 17617287
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg packet (sachet) formulation
Study: 11773946
Drug: Biologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapies (anti-tumour necrosis factor-alpha, interleukin-10, interleukin-11, anti-integrin antibody, antisense intercellular adhesion molecule-1 oligonucleotide)
Study: 11122690
Drug: Lovastatin therapy
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin therapy
Study: 15345500
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily
Study: 12521407
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch
Study: 20639026
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg serlopitant
Study: 20639026
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg serlopitant
Study: 31087047
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment orders
Study: 19844249
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of estrogen therapy
Study: 16647134
Drug: Pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib sodium (0.3 mg)
Study: 2991475
Drug: Intravenous hyperalimentation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyperalimentation (IVH)
Study: 30895944
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol plus 5‐fluorouracil (5‐FU)
Study: 7727328
Drug: Isobaric tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isobaric tetracaine (IT) at varying doses and volumes
Study: 17908628
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with chemotherapy
Study: 17938794
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of rFVIIa (50 microg/kg/h through day 5, then 25 microg/kg/h for days 6-10)
Study: 11386894
Drug: Warfarin in
Normalized name: warfarin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin in randomized trials
Study: 25575246
Drug: EW nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: EW nebulizer with 30-second inhalation
Study: 9347673
Drug: Ketoprofen hydroalcoholic
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen hydroalcoholic gel, applied at the painful site four times a day for 4 weeks
Study: 8212152
Drug: Short taper
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short taper group (total PRED dose of 2275 mg/m2 over 86 days)
Study: 8212152
Drug: Long taper
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long taper group (total PRED dose of 6300 mg/m2 over 147 days)
Study: 19828484
Drug: High magnesium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High magnesium levels (>1.0 mmol/l)
Study: 26689783
Drug: Rivaroxaban in
Normalized name: Product containing rivaroxaban in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone
Study: 22732511
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus albumin (1.5 g/kgbw at diagnosis and 1 g/kgbw at day 3); n=56
Study: 31894027
Drug: Valsartan dispersible
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan dispersible tablets
Study: 31894027
Drug: Nifedipine controlled-release
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine controlled-release tablets combined with valsartan
Study: 16141376
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (300 mg oral ranitidine)
Study: 24670148
Drug: Paromomycin-miltefosine combination
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin-miltefosine combination therapy
Study: 2254102
Drug: Classical radiation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical radiation therapy (IC) - 45 Gy in 25 fractions over 33 days
Study: 1320919
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron 40 micrograms/kg
Study: 8429117
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg bid
Study: 8429117
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg bid
Study: 25323890
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (NaP) tablets
Study: 1843963
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) solution
Study: 22960196
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion [2.0 pmol kg(‐1) min(‐1) for 240 min]
Study: 25609246
Drug: Ganitumab 12
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 12 mg/kg
Study: 8035693
Drug: Blocked lists
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocked lists of color patches
Study: 15834325
Drug: Information Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information Group (nonelastic sacroiliac belt and oral/written information about pelvic girdle pain)
Study: 7001898
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment group.
Study: 28884732
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (n=44)
Study: 12048134
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg/day for up to 104 weeks
Study: 25688120
Drug: Dose-dense temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-dense temozolomide
Study: 2151435
Drug: Picotamide 300
Normalized name: picotamide
DrugBank: Picotamide (DB13327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide 300 mg t.i.d. for 10 days
Study: 15631278
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 16 mg plus hydrochlorothiazide (HCTZ) 12.5 mg
Study: 11603446
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (6 mmol MgSO4 in 100 mL 0.9% NaCl solution, 25 mL/h) administered the day before surgery, just after cardiopulmonary bypass, and once daily for 4 days after surgery
Study: 10994682
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy integrated into Day Treatment Program (CBT/DTP)
Study: 21656058
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention
Study: 30409942
Drug: CPP-ACP chewing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPP-ACP chewing gums, used thrice daily for 2 weeks
Study: 11450504
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg gliclazide (study 1)